Lin Chen, Wang Yujie, Lin Xiao, Ren Chufan, Wang Yifeng, Ma Yizhong, Zhou Jiahao, Gu Chuyu, Wang Jianyi
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China.
The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Discov Oncol. 2025 Jun 16;16(1):1124. doi: 10.1007/s12672-025-02708-8.
Liver cancer (LC) is a prevalent malignancy characterized by insidious onset, high recurrence rates, and significant mortality. The herbal combination "Citri Reticulatae Pericarpium-Reynoutria japonica" (CR) has traditionally been used for managing LC and related disorders, demonstrating notable therapeutic efficacy. This study aims to identify the molecular targets of CR in LC and assess its pharmacological properties and potential toxicity.
We used GeneCards, OMIM, and TTD databases to identify targets associated with liver cancer and constructed protein-protein interaction (PPI) and herbal-target-pathway-disease interaction networks. We performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses to explore the molecular mechanisms of CR. We also used differential expression analysis with GEO datasets (GSE76427, GSE87630, and GSE112790) to validate liver cancer-related targets and identify common core targets.
Survival analysis indicated that HSP90AA1 may serve as a potential biomarker for LC. Molecular docking studies showed that rhein, a compound in CR, has a strong binding affinity to the identified target proteins. This research provides robust theoretical support for the clinical application of CR in treating LC, especially in cases related to non-alcoholic fatty liver disease (NAFLD) or Metabolic Lipid Disorders (DLM).
肝癌(LC)是一种常见的恶性肿瘤,具有起病隐匿、复发率高和死亡率高的特点。传统上,中药复方“陈皮-虎杖”(CR)一直用于治疗肝癌及相关疾病,显示出显著的治疗效果。本研究旨在确定CR在肝癌中的分子靶点,并评估其药理特性和潜在毒性。
我们使用GeneCards、OMIM和TTD数据库来识别与肝癌相关的靶点,并构建蛋白质-蛋白质相互作用(PPI)和草药-靶点-通路-疾病相互作用网络。我们进行了基因本体论(GO)和京都基因与基因组百科全书(KEGG)通路富集分析,以探索CR的分子机制。我们还使用GEO数据集(GSE76427、GSE87630和GSE112790)进行差异表达分析,以验证肝癌相关靶点并识别共同的核心靶点。
生存分析表明,HSP90AA1可能作为肝癌的潜在生物标志物。分子对接研究表明,CR中的化合物大黄酸与鉴定出的靶蛋白具有很强的结合亲和力。本研究为CR在肝癌治疗中的临床应用,特别是在非酒精性脂肪性肝病(NAFLD)或代谢性脂质紊乱(DLM)相关病例中的应用,提供了有力的理论支持。